反应详情

In a similar manner to that described in example 196, from ethyl 1-(4-fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate(15 mg, 0.0344 mmol) and [2-(4-morpholinyl)ethyl]amine (0.05 mL) was prepared 1-(4-fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (10 mg, 56% yield) as a yellow solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.03 (br s, 1 H), 8.51 (s, 1 H), 7.29-7.24 (m, 2 H), 7.20-7.16 (m, 2 H), 7.01-6.91 (m, 4 H), 6.69 (s, 1 H), 3.93 (s, 2 H), 3.68 (m, 4 H), 3.56 (m, 2 H), 2.59 (m, 2 H), 2.51 (m, 4 H); MS m/z 521 (M+1).